替米沙坦与二甲双胍联合降压可改善糖脂代谢

2012-04-20 晓静 编辑 医学论坛网

  发表于2012年第3期《中华高血压杂志》上研究表明,替米沙坦与二甲双胍联合治疗能够改善高血压合并非酒精性脂肪性肝病(NAFLD)患者的血压和糖脂代谢。   研究者将高血压合并NAFLD患者60例根据治疗方案分为对照组和观察组,对照组单用替米沙坦治疗,观察组给予替米沙坦和二甲双胍联合治疗,观察时间6月。观察两组治疗前后血压、腰臀比、体质量指数(BMI))、总胆固醇、三酰甘油、低密度脂蛋白胆固醇

  发表于2012年第3期《中华高血压杂志》上研究表明,替米沙坦与二甲双胍联合治疗能够改善高血压合并非酒精性脂肪性肝病(NAFLD)患者的血压和糖脂代谢。

  研究者将高血压合并NAFLD患者60例根据治疗方案分为对照组和观察组,对照组单用替米沙坦治疗,观察组给予替米沙坦和二甲双胍联合治疗,观察时间6月。观察两组治疗前后血压、腰臀比、体质量指数(BMI))、总胆固醇、三酰甘油、低密度脂蛋白胆固醇(LDL-C)、稳态模型胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMAβ)和胰岛素敏感指数(ISI)等指标变化。

  结果显示,治疗前两组患者的基线资料、血压、血脂和糖代谢指标差异无统计学意义(P>0.05)。治疗6月后,与治疗前比较,两组患者血压、血脂和糖代谢指标得到改善(均P<0.05);与对照组比较,观察组患者的血压、血脂和糖代谢指标改善更明显(均P<0.05)。

  相关链接:替米沙坦与二甲双胍联合治疗对高血压合并非酒精性脂肪性肝病患者血压和糖脂代谢的影响



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1254857, encodeId=b43d125485e85, content=<a href='/topic/show?id=78b3e6858b7' target=_blank style='color:#2F92EE;'>#糖脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76858, encryptionId=78b3e6858b7, topicName=糖脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291763, encodeId=693c1291e6396, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543189, encodeId=4d7a1543189c4, content=<a href='/topic/show?id=f34e60352cb' target=_blank style='color:#2F92EE;'>#替米沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60352, encryptionId=f34e60352cb, topicName=替米沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f1713553868, createdName=hittouch, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597054, encodeId=dfc5159e0541c, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1254857, encodeId=b43d125485e85, content=<a href='/topic/show?id=78b3e6858b7' target=_blank style='color:#2F92EE;'>#糖脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76858, encryptionId=78b3e6858b7, topicName=糖脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291763, encodeId=693c1291e6396, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543189, encodeId=4d7a1543189c4, content=<a href='/topic/show?id=f34e60352cb' target=_blank style='color:#2F92EE;'>#替米沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60352, encryptionId=f34e60352cb, topicName=替米沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f1713553868, createdName=hittouch, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597054, encodeId=dfc5159e0541c, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1254857, encodeId=b43d125485e85, content=<a href='/topic/show?id=78b3e6858b7' target=_blank style='color:#2F92EE;'>#糖脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76858, encryptionId=78b3e6858b7, topicName=糖脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291763, encodeId=693c1291e6396, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543189, encodeId=4d7a1543189c4, content=<a href='/topic/show?id=f34e60352cb' target=_blank style='color:#2F92EE;'>#替米沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60352, encryptionId=f34e60352cb, topicName=替米沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f1713553868, createdName=hittouch, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597054, encodeId=dfc5159e0541c, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1254857, encodeId=b43d125485e85, content=<a href='/topic/show?id=78b3e6858b7' target=_blank style='color:#2F92EE;'>#糖脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76858, encryptionId=78b3e6858b7, topicName=糖脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291763, encodeId=693c1291e6396, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543189, encodeId=4d7a1543189c4, content=<a href='/topic/show?id=f34e60352cb' target=_blank style='color:#2F92EE;'>#替米沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60352, encryptionId=f34e60352cb, topicName=替米沙坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f1713553868, createdName=hittouch, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597054, encodeId=dfc5159e0541c, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sun Apr 22 10:12:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
    2012-04-22 huangdf

相关资讯

运动降低高血压患者的CVD死亡风险

  根据2012年世界心脏病学大会4月19日公布的一项最新研究,高血压患者通过运动所减少的心血管疾病(CVD)或全因死亡风险相当于血压下降40~50mmHg所产生的影响。   在此研究中,与各血压水平的运动受试者相比,不运动的受试者其全因和CVD死亡风险显著升高。此外,不运动造成了过量死亡危险。当把运动换算成血压指标时,结果显示不运动与血压上升40~50mmHg所致死亡风险的增高相似。

肾病患者血压低于140/90即达标

    最近,KDIGO基金会建议将针对慢性肾病患者的血压目标值设为140/90 mmHg以下,而2003年美国预防、检测、评估与治疗高血压全国联合委员会第七次报告(JNC 7)中设定的目标值为130/80 mmHg。       芝加哥大学高血压中心主任George L. Bakris博士参与了这2次编写工作,他介绍了3项支持这一变更的随机对

更换或添加药物或可解决噻嗪类诱导糖尿病

  英国学者的一项研究表明,替换药物或添加阿米洛利可能是预防噻嗪类诱导糖尿病的解决方案。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   高血压指南建议限制噻嗪类利尿剂用量并避免联用β受体阻滞剂,原因在于其可升高糖尿病风险。研究者实施了两项双盲、安慰剂对照、交叉研究。在纳入41例患者的第一项研究中,苄氟噻嗪治疗4周后可检查到2小时口服糖耐量试验时的血糖

更换或添加药物或可解决噻嗪类诱导糖尿病

  英国学者的一项研究表明,替换药物或添加阿米洛利可能是预防噻嗪类诱导糖尿病的解决方案。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   高血压指南建议限制噻嗪类利尿剂用量并避免联用β受体阻滞剂,原因在于其可升高糖尿病风险。研究者实施了两项双盲、安慰剂对照、交叉研究。在纳入41例患者的第一项研究中,苄氟噻嗪治疗4周后可检查到2小时口服糖耐量试验时的血糖

If通道阻滞剂或具心衰预防额外益处

  德国学者的一项研究表明,除降低心率外,If通道(If-Channel)阻滞剂可通过预防心衰对心脏产生额外积极影响。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   此项研究通过置入持续性皮下释放血管紧张素Ⅱ的渗透泵在C57BL/6J小鼠中诱导心功能不全;诱导持续时间超过3周。伊伐布雷定和美托洛尔可产生相同程度的心率降低。将上述两种药物或安慰剂治疗与血管紧张素

碳水化合物摄入过量对青春期血压有不良影响

  澳大利亚学者的一项研究表明,碳水化合物膳食摄入过量可对血压产生不良影响,并且在女孩中尤为显著,富含纤维膳食具有防治青春期血压升高的潜力。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   此项研究前瞻性评估了摄入食物的血糖指数和血糖负荷以及碳水化合物、糖、纤维等食物组膳食摄入与青春期内血压变化的相关性。研究于基线时纳入858例年龄为12岁的学生,其中男、女孩分